Observe The Efficacy Of Thalidomide Combined With Chemotherapy Treat On Multiple Myeloma Patient And In The Impact Of IL-6and VEGF

Objective To observe the efficacy of the thalidomide combined VAD [Vincristine (VCR), Adriamycin (ADM), Dexamethasone (DEX), T-VAD)] in the treatment of mul-tiple myeloma (Multiple Myeloma, MM), and the adverse reaction as well as; by observing the T-VAD in the treatment of MM on serum levels of interleukin-6(IL-6) and vascular endothelial cell growth factor (VEGF) explore the relationship of IL-6and VEGF with the mechanism of pathogenesis of MMMethods Collect30newly diagnosed and relapsed MM patients, observe the efficacy and adverse reactions of T-VAD, to do regular tests of blood routine、urine routine, ESR, liver、renal function, calcium, phosphorus, glucose, quantitative immunoglobulin, light chain, protein electrophoresis, blood lactate dehydrogenase, as well as bone marrow puncture and other tests, observe the efficacy of T-VAD program, record the adverse reactions; Detect serum IL-6and VEGF levels pre-treatment and2,3-course after treatment using ELISA method and compared with normal control groupResults T-VAD in the treatment of MM patients with complete remission rate was36.7%, partial remission rate was56.7%, with a total effective rate was93.4%. The adverse reactions are mainly fatigue, constipation, nausea, drowsiness, skin rash, peripheral neuropathy, were no significant bone marrow suppression. MM patients with serum IL-6[(15.97±2.97) pg/ml,p<0.01] and VEGF [(582.43±40.97) pg/ml, p<0.01] were significantly higher than the nor-mal control group, IL-6[(5.94±1.33) pg/ml] and VEGF [(95.71±25.04) pg/ml], T-VAD in the treatment of MM treatment serum IL-6[(10.53±2.48) pg/ml, p <0.01] and VEGF [(330.97±44.91) pg/ml, p<0.01] levels in serum were signifi-cantly decreased after treatment with T-VAD programConclusion The treatment of T VAD program has good curative effect for MM patient, good compliance with low-dose thalid-omide,and the adverse reaction is trifling. IL-6and VEGF levels in serum of MM patients increase significantly; IL-6and VEGF levels in serum decrease significantly after treatment with T-VAD program.